{
  "nctId": "NCT05792085",
  "briefTitle": "Heart Failure Optimization at Home to Improve Outcomes (Hozho): A Pragmatic Clinical Trial in Navajo Nation",
  "officialTitle": "Heart Failure Optimization at Home to Improve Outcomes (Hozho): A Pragmatic Clinic Trial of Telephone-Based GDMT Optimization in Navajo Nation",
  "protocolDocument": {
    "nctId": "NCT05792085",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2022-09-06",
    "uploadDate": "2023-08-23T01:15",
    "size": 445464,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05792085/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "SEQUENTIAL",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 103,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2023-02-01",
    "completionDate": "2023-08-01",
    "primaryCompletionDate": "2023-08-01",
    "firstSubmitDate": "2023-01-26",
    "firstPostDate": "2023-03-30"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients with heart failure with reduced ejection fraction with last ejection fraction equal to or less than 40%\n* Have a primary care physician at Gallup Indian Medical Center or Tohatchi Health Center\n* Have been seen in the last 12 months at Gallup Indian Medical Center or Tohatchi Health Center\n\nExclusion Criteria:\n\n* On hospice\n* LVAD/translant\n* Home inotropes\n* No visit in last 12 months at Gallup Indian Medical Center or Tohatchi Health Center",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage That Had Increase in Classes of Guideline Directed Medical Therapy",
        "description": "% of Patients that had Increase in the number of classes of Guideline Directed Medical Therapy (Beta-blocker, ACEi/Angiotensin receptor blockers, Angiotensin Receptor-Neprilysin Inhibitor, Aldosterone receptor antagonists, SGLT2i)",
        "timeFrame": "30 days"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage That Had Increase in Classes of Guideline Directed Medical Therapy or Dose of Guideline Directed Medical Therapy",
        "description": "Proportion of patients that had an increase in the number of classes or dose of Guideline Directed Medical Therapy (Beta-blocker, Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers, Angiotensin Receptor-Neprilysin Inhibitor, Aldosterone receptor antagonists, Sodium-glucose co-transporter 2 inhibitors)",
        "timeFrame": "30 days"
      },
      {
        "measure": "Rates of Increase/Addition of ACEi/ARB/Angiotensin Receptor-Neprilysin Inhibitor",
        "description": "Rates of Rx for ACEi, ARB, or ANRI (Sacubritril-Valsartan)",
        "timeFrame": "30 days"
      },
      {
        "measure": "Rates of Increase/Addition in Sodium-glucose Co-transporter 2 Inhibitors",
        "description": "Rates of Rx for Sodium-glucose co-transporter 2 inhibitors",
        "timeFrame": "30 days"
      },
      {
        "measure": "Rates of Increase/Addition of Aldosterone Receptor Antagonists",
        "description": "Rates of Rx for Aldosterone receptor antagonists",
        "timeFrame": "30 days"
      },
      {
        "measure": "Rates of Increase/Addition of Beta-blockers",
        "description": "Rates of Rx for Beta-blockers",
        "timeFrame": "30 days"
      },
      {
        "measure": "Addition of or Increase in Dose for ACEi/ARB/ARNI",
        "description": "Increase in Dose for ACEi/ARB/ARNI",
        "timeFrame": "30 days"
      },
      {
        "measure": "Addition of or Increase in Dose of Beta-blocker",
        "description": "Addition of or Increase in Dose for Beta-blocker",
        "timeFrame": "30 days"
      },
      {
        "measure": "Addition of or Increase in Dose of Aldosterone Receptor Antagonists",
        "description": "Dose increase or addition of Aldosterone receptor antagonists",
        "timeFrame": "30 days"
      }
    ],
    "other": [
      {
        "measure": "Change in Provider Comfort With Guideline Directed Medical Therapy Prescribing From Baseline to 6 Months",
        "description": "Baseline and follow up comfort prescribing therapy: Through survey we will assess at baseline and on follow-up how comfortable (from 1-5) providers feel with prescribing each of the following medications: Beta-blocker, Aldosterone receptor antagonist, Angiotensin-converting enzyme inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, Sodium-glucose co-transporter 2 inhibitors. This measure is a score on a scale from 1-5, with 1 indicating low comfort level and 5 indicating high comfort level.",
        "timeFrame": "6 months"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 8,
      "otherCount": 1,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "SEQUENTIAL"
    },
    "overallComplexityScore": 81,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:33.264Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}